Slides
Page 1
Third Quarter 2026 Earnings November 3, 2026
Page 2
Safe Harbor This presentation contains "forward - looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end - markets, plans concerning business development opportunities, acquisitions or divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward - looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward - looking statements. A detailed description of these risk factors can be found under the caption “Risk Factors” in our most recent quarterly report on Form 10 - Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward - looking statements as a result of developments occurring after the date of this presentation. In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non - GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded hyperlink and is available on the “Financial Information” section of our website at www.revvity.com. 2
Page 3
Key Takeaways Innovation Market Performance Launched 3 - plex solution for early detection of T1D Announced acquisition of Human Cell Design 3Q financial performance above expectations Volume and operational efficiency drove meaningful margin expansion Strong cash flow and retired €500m note Improving Pharma/Biotech end market conditions AI - related demand continuing to build Strong Diagnostic trends outside of China A Scientific Solutions Company Helping to Solve The World's Greatest Health Challenges From Discovery to Development, and Diagnosis to Cure 3
Page 4
4 3Q26 Pro Forma* Revenue Highlights Life Sciences Segments Geographic Product Mix +DD +DD - LSD $0.7B +HSD +MSD +HSD - LSD $0.7B $0.7B Diagnostics AMERICAS APAC EU Recurring Non - recurring *Pro Forma excludes the impact of the China Immunodiagnostics business which the Company has agreed to divest
Page 5
3Q26 Financial Results 5 PRO FORMA REVENUE PRO FORMA ADJ. OP. MARGIN PRO FORMA ADJ. EPS FREE CASH FLOW $710M +7% y/y 29.4% +340bps y/y $1.37 +21% y/y Organic: +7% | M&A: +1% | FX: - 1% Adj. Gross Margin: 62.4% | +280bps y/y Adj. Tax Rate: 18.2% Adj. Net Interest & Other: $21M $152M YTD FCF % Adj. NI: 105% Pro Forma excludes the impact of the China Immunodiagnostics business which the Company has agreed to divest; Reconciliations to the most directly comparable GAAP measure for the non - GAAP terms presented above are provided on our website and in this hyperlink $451M YTD
Page 6
$380M 3Q26 pro forma revenue LIFE SCIENCES SOLUTIONS 6 Life Sciences +9% Total: +11% | M&A: +2% | FX: 0 % Organic Growth 31.5% +200bps y/y PRO FORMA REVENUE ADJUSTED OP. MARGINS +HSD +DD • +LDD Pharma/Biotech & +MSD Academic/Gov’t • +HSD Life Sciences Solutions, with both reagents and instruments delivering growth ahead of expectations • +DD software, driven by contract renewals and ARR growth • Margin improvement yr/yr driven by volume leverage and favorable product mix SOFTWARE Pro Forma revenue excludes the impact of the China Immunodiagnostics business which the Company has agreed to divest ; Reconciliations to the most directly comparable GAAP measure for the non - GAAP terms presented above are provided on our website and in this hyperlink
Page 7
7 Diagnostics • +HSD ImmunoDx with strength in the Americas • +LSD Reproductive Health with +MSD growth ex - China • Significant margin improvement yr/yr driven by volume leverage and benefit of operational efficiency • Dx adj. Op. Margin includes 160bps headwind from China ImmunoDx +5% Total: +4% | M&A: 0% | FX: - 1% 29.9% +480bps y/y PRO FORMA REVENUE ADJUSTED OP. MARGINS $330M 3Q26 pro forma revenue +HSD +LSD Pro Forma revenue excludes the impact of the China Immunodiagnostics business which the Company has agreed to divest; Reconci lia tions to the most directly comparable GAAP measure for the non - GAAP terms presented above are provided on our website and in this hyperlink IMMUNODIAGNOSTICS REPRODUCTIVE HEALTH Organic Growth
Page 8
2026 Pro Forma* Financial Guidance 8 REVENUE ~$2.86B $5.40 - $5.45 Total : ~6% Organic: ~ 5% FX: +0.5%, M&A: +0.75 % ADJUSTED OP. MARGIN ~28.8% ADJUSTED EPS Adj. net interest expense, other: ~$88M Adj. tax rate: ~ 18 % Average diluted share count: ~112M *Pro Forma excludes the impact of the China Immunodiagnostics business which the Company has agreed to divest
Page 9
Revvity.com